Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tubulin tyrosine ligase-like protein 2 (TTLL2) is an enzyme belonging to the tubulin tyrosine ligase-like family, predicted to catalyze the generation of polyglutamate side chains on the gamma-carboxyl group of specific glutamate residues in the C-terminal tail of target proteins, notably tubulins[1][7]. TTLL2 likely participates in the post-translational polyglutamylation of tubulin, a modification crucial for microtubule function and organization[1][7]. It may require interaction with other protein partners for full enzymatic activity and is implicated in the initiation of polyglutamylation rather than its elongation[7]. TTLL2 is associated with some cancers, including large intestine adenocarcinoma, but specific therapeutics targeting TTLL2 have not been reported[1]. Its expression and functional relevance have also been noted in testis and ciliary basal body, suggesting roles in cilia function and spermatogenesis[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin tyrosine ligase-like protein 2 (TTLL2).